Arizona State University

Arizona Board of Regents, a Body Corporate

Huafang Lai

Qiang Chen

Ming Yang

Jonathan Hurtado

Junyun He

Haiyan Sun

The present invention relates to the fields of genetically modifiedstrains, vaccine adjuvants, and generally molecular biology and immunology. Provided herein are modifiedstrains that produce lipopolysaccharide (LPS) having reduced toxicity or detoxified lipopolysaccharide, and methods of obtaining such strains for plant-based production of biologies. Also provided herein are uses of reduced or detoxified LPS as adjuvants suitable for clinical use.

Reducing the toxicity of agrobacterium endotoxin

Compositions including a virus-like particle (VLP)-based vaccine displaying a portion of ZIKV envelope protein (E) domain III (DIII) and a portion of ZIKV envelope protein (E) and related methods are disclosed herein. Further, compositions including vaccines comprising a portion of ZIKA virus E protein, wherein the portion of ZIKA virus E protein is either a full-length version of ZIKA virus E protein or a functionally equivalent version of the full-length ZIKA virus E protein, are disclosed.

Vaccines against Zika virus based on Zika structure proteins

The present invention describes the plant-based production of a therapeutic anti-virus antibody.

Plant-derived antibodies and derivatives that reduce risk of antibody-dependent enhancement (ADE) of infection

The plant-based production of a therapeutic antibody against West Nile Virus is disclosed.

Bispecific monoclonal antibody therapeutics against West Nile virus with improved CNS penetration

The present invention describes the plant-based production of a therapeutic antibody against West Nile Virus.

Growing community of inventors

Chandler, AZ, United States of America

Huafang Lai